Why Does The Smart Money Like Acorda Therapeutics?
Acorda Therapeutics Inc (NASDAQ:ACOR) is a $1.11 billion biotechnology company that develops and commercializes novel therapies for neurological disorders.
Acorda Therapeutics Inc. (ACOR)
Market is closed
News
- First
- << Previous
- 31 - 40
- Next >>
Two Big Parkinson’s Updates From Adamas Pharmaceuticals Inc (ADMS) And Acorda Therapeutics Inc (ACOR)
We just got a couple of updates in the Parkinson’s space, and both have the potential to serve up some volatility in the market capitalisations of the companies in question.
Should You Buy Acorda Therapeutics Inc (ACOR)?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.
These Oil and Biotech Stocks Are in the Crosshairs of Elite Investors
While many hedge funds are still preparing their third quarter filings with the SEC, providing the main ingredients for our delectable small-cap investment strategy, some managers are already disclosing...
Kyle Bass' War Against Pharmaceutical Companies Goes On While The Masses Overlook China's Real Problem
Those who seek to profit from shorting strategies should keep a close eye on Kyle Bass’ war against the pharmaceutical industry.
Acorda Therapeutics Inc (ACOR)’s Shares Jump After Dismissal Of Patent Challenge From Hedge Fund Manager Kyle Bass
The shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are trading 13.16% higher today after the dismissal of a patent challenge against the company.
Nektar Therapeutics (NKTR): Insiders Aren't Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Acorda Therapeutics Inc (ACOR): Insiders Aren't Crazy About It But Hedge Funds Love It
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Alnylam Pharmaceuticals, Inc. (ALNY): Insiders Aren't Crazy About It But Hedge Funds Love It
If you were to ask many market players, hedge funds are seen as useless, outdated financial tools of a period lost to current times.
- First
- << Previous
- 31 - 40
- Next >>
Billionaire Hedge Funds
